ClinicalTrials.gg
RecruitingNCT07580222Updated May 12, 2026

Mobile Technology to Measure Knee Health in Osteoarthritis

An observational study in Osteoarthritis, Knee, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by VA Office of Research and Development · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
47
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Osteoarthritis, Knee by VA Office of Research and Development — 7 open to participants now, 8 under way, 2 of them phase 3. Osteoarthritis, Knee · VA Office of Research and Development.

Started
2026
with 3 others
Observational
Only one
of the 17
Registered
15th of 17
by date

Among the 17 studies in Osteoarthritis, Knee by VA Office of Research and Development, this one is one of 4 that started in 2026, is the only observational one, and was the 15th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

7 of the 17 studies in Osteoarthritis, Knee by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Osteoarthritis, Knee by VA Office of Research and Development, or all of them as a file.
02

Study summary

Veterans face a high prevalence of knee osteoarthritis (OA), but current diagnostic methods often miss early stages when interventions are more effective. This project will evaluate smartphone-based motion capture via OpenCap to measure joint mechanics in knee OA patients during functional activities, comparing its performance to a conventional motion capture system, patient-reported symptoms, and knee joint structure. The findings will have the potential to enable clinicians to trial OpenCap in its current form, provide insights into tracking joint health, and guide refinements to advance toward earlier diagnosis of knee OA by complementing symptom assessments with measures of joint mechanics.

Read the detailed description

Significance to VA: Veterans, particularly the younger age group, have a higher prevalence of osteoarthritis (OA) than the general population. Among Veterans, OA most commonly affects the knee, a joint with a high injury rate in the US Military. Current diagnostic criteria for knee OA, which often rely on radiographic evidence, do not consistently identify younger patients or those in the early stages of OA, when interventions may be most effective. At the onset of OA symptoms, there is a critical window to quantify mechanical markers that could predict disease progression and provide insights beyond pain. While mechanical markers are predictive and capable of tracking OA progression, their clinical utility has been limited by conventional marker-based motion capture (Mocap), which requires specialized equipment, trained experts, and dedicated resources, making it inaccessible in many clinical settings.

Innovation and Impact: A novel mobile technology, OpenCap, uses smartphone video-based motion capture to estimate movement mechanics, offering a low-cost and highly accessible alternative to traditional Mocap. OpenCap requires at a minimum of two smartphones and applies machine learning and musculoskeletal modeling to quantify mechanical markers. This technology has the potential to overcome significant barriers to implementing mechanical markers in clinical care. However, OpenCap has not yet been evaluated in knee OA patients, and its validity for quantifying mechanical markers during activities relevant to knee OA management remains underexplored.

Therefore, this mentored career development award application has an objective to evaluate the utility of mobile technology OpenCap in quantifying mechanical markers that may provide insights into joint health in patients with early knee OA and to extract these markers from functional activities commonly used in knee OA management.

Specific Aims: Aim 1 will evaluate the current potential use of the mobile technology OpenCap in patients with knee OA by testing the hypotheses that (1a) mechanical markers estimated by the mobile technology significantly differ but are associated with those measured using conventional Mocap and (1b) the mobile technology detects within-person, within-visit mechanical differences introduced by functional activity variations. Aim 2 will explore the broader use of the mobile technology OpenCap in patients with knee OA by (2a) associating mechanical markers estimated by the mobile technology with patient-reported outcomes (PROs), performance-based measures, and structural metrics and (2b) determining the test-retest reliability of the mechanical markers.

Anticipated Research Outcomes: The project findings will have the potential to enable clinicians to trial the technology in its current form, leveraging its potential to quantify and document movement mechanics in patients at risk of or with knee OA. At the same time, the project's results will explore more advanced applications, such as tracking functional changes over time during OA treatment and contributing critical data to refine and further develop the technology. On the other hand, recalling an existing research cohort offers an invaluable opportunity for longitudinal follow-up.

Anticipated Training Outcomes: This award will provide the applicant with training in musculoskeletal modeling, data science, and clinical and translational science, enabling the applicant to validate and refine mobile motion capture technologies. This training will prepare the applicant to integrate mobile technologies into clinical practice and support applicant's advancement to independence through next-level CDA award.

Path to Translation/Implementation: This study will provide clinicians with practical insights on using OpenCap in its current form to quantify and document joint health. Findings will inform future refinements and support subsequent efforts to evaluate the feasibility of video-based motion capture via OpenCap in OA care. This project aligns with VA priorities by improving early diagnosis and management of knee OA to enhance care for Veterans.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals who were diagnosed with early knee osteoarthritis and had a history of being elected to receive injection treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veteran and non-Veterans
  • males and females
  • diagnosed with early knee osteoarthritis
  • qualified for and participated in the Precision Assessment of Rich Plasma for Joint Preservation study (ClinicalTrials.gov ID: NCT03460236)
  • able and willing to provide for follow-up study

Exclusion criteria

Exclusion Criteria:

  • symptomatic OA in joints other than the knee in the lower body
  • joint replacement
  • rheumatic disease
  • > 35 kg/m\^2
  • severe systematic disease defined as (ASA) 3 or above
  • pregnant or intending to become pregnant during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
47 participants (estimated)
Patient registry
No

Groups and cohorts

  • Knee OA

    Adults who were previously diagnosed with early knee osteoarthritis, enrolled in Precision Assessment of Platelet Rich Plasma for Joint Preservation study (NCT03460236), and able and willing to participate in the follow-up assessment.

06

What researchers measure

Primary outcomes

  1. Knee flexion angle

    Knee flexion angle extracted from functional activities (e.g., walking, chair-to-stand)

    Time frame: Baseline and Week 1

Secondary outcomes

  1. Knee flexion moment

    Knee flexion moment estimated from functional activities (e.g., walking, chair-to-stand)

    Time frame: Baseline and Week 1

Other outcomes

  1. Western Ontario and McMaster Universities Osteoarthritis Index (Transformed)

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores will be calculated from answers to the Knee Injury and Osteoarthritis Outcome Score questionnaire, including domains of Pain, Stiffness, and Function. WOMAC scores will be transformed to a scale of 0-100, with higher scores indicating fewer symptoms.

    Time frame: Baseline and Week 1

  2. Duration of 40-meter fast walk test

    Duration in seconds to complete 40-meter fast walk test

    Time frame: Baseline or Week 1

  3. Repetitions for 30-second chair-to-stand test

    The number of repetitions of chair-to-stand performed during 30-second

    Time frame: Baseline or Week 1

07

Study locations

1 of 1 sites recruiting
  • VA Palo Alto Health Care System, Palo Alto, CA
    Palo Alto, California 94304-1207, United States
    Recruiting
    • Jade He, PhD · ContactJade.He@va.gov · 650-493-5000
    • Jade He, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 179 non-industry observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 17 months is below that.

Counting every sponsor, half of 220 studies reached it within 24 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
May 12, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07580222
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Apr 1, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
May 12, 2026

Study contacts

Jade He, PhD
Contact
Jade.He@va.gov
(650) 493-5000 ext. 64431
Jade He, PhD
principal investigator · VA Palo Alto Health Care System, Palo Alto, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion